ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "🪙 Double Trouble or Dual Protection? 💊💊🛡️ Ticagrelor and Aspirin After CABG—What Did We Learn?"
Episode Synopsis
🧠 TACSI Trial in NEJM (Sep 2025) challenges the status quo on dual antiplatelet therapy after CABG for ACS! 👨⚕️ 2201 patients across 5 Nordic countries 💊 Ticagrelor + Aspirin ≠ better outcomes vs Aspirin alone 📉 No reduction in death, MI, stroke, or revascularization 🩸 But bleeding (4.9% vs 2.0%) & dyspnea (18.2% vs 6.4%) increased 📚 Guidelines may need rethinking. 📖 Jeppsson A et al. N Engl J Med. 2025; DOI: 10.1056/NEJMoa2508026 #TACSI #Cardiology #CABG #DAPT #ACS #NEJM #PrecisionMedicine #RCT #BleedingRisk #ClinicalTrials
In God we trust